> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Bicara Stock Soars 9% After Results — Its Cash Runway Extends Into Early 2029
- URL: https://www.bullished.co/bicara-stock-soars-9-after-results-its-cash-runway-extends-into-early-2029-03e02463/
- Published: 2026-11-09T16:47:36.000Z
- Updated: 2026-11-09T16:47:36.000Z
- Description: The cancer-drug developer's quarterly loss widened as trial and staffing costs rose, with pivotal trial results expected in mid-2027.
- Author: Matteo Parrino
- Tags: Markets, BCAX, Industry: Healthcare

[Bicara Therapeutics](https://www.bullished.co/tag/bcax/), which develops experimental treatments for solid tumors, soared 8.90% to $9.42 in Monday trading, as of 11:45 a.m. ET, adding $51 million in market value after its results. On Monday's earnings call, management discussed [shifting launch assumptions](https://www.benzinga.com/news/26/11/63033031/bicara-therapeutics-q3-2026-earnings-call-transcript?ref=bullished.co) toward survival evidence as rival competition intensifies; the company expects its cash to last into the first half of 2029.

## A Rebound After A 48% Slide

BCAX shares were on pace for their second gain of 7% or more this month in Monday trading. Bicara's market value stood at $623.35 million in that session.

The rebound follows a sharp retreat. At Friday's close, Bicara was down 49% year-to-date, while the S&P 500 had gained 8%. The stock had lost 48% over the previous month.

## Trial Costs Widen The Loss

Bicara's third-quarter net loss reached [$71.2 million](https://www.sec.gov/Archives/edgar/data/0002023658/000162828026071886/bcax-20261109.htm?ref=bullished.co), compared with $36.3 million a year earlier, according to Monday's SEC filing. Higher trial and staffing costs were the primary factors accompanying the wider loss.

Cash and investments totaled [$442.3 million](https://www.sec.gov/Archives/edgar/data/0002023658/000162828026071886/bcax-20261109.htm?ref=bullished.co), against $414.8 million at year-end 2025\. Management projects that funding will cover operations into the first half of 2029.

The company's earlier quarterly report recorded a [$55.4 million loss](https://www.sec.gov/Archives/edgar/data/2023658/000162828026055765/bcax-20260630.htm?ref=bullished.co) for the period ended June 30.

## Ficerafusp Alfa's Head And Neck Test

Bicara reported [substantial enrollment](https://www.globenewswire.com/news-release/2026/11/09/3398297/0/en/bicara-therapeutics-reports-third-quarter-2026-financial-results-and-provides-business-update.html?ref=bullished.co) in its pivotal head and neck cancer trial in Monday's business update. The ongoing global mid- to late-stage study tests its lead candidate, ficerafusp alfa, alongside pembrolizumab.

Ficerafusp alfa pairs a cancer-targeting antibody with a component intended to block signals that promote tumor growth and suppress immune activity. Bicara also studies the candidate in colorectal cancer and other solid tumors.

The company remains a clinical-stage drug developer: its treatments are being tested in patients through trials rather than sold commercially.

Bicara expects the pivotal head and neck study's initial interim analysis results in [mid-2027](https://www.globenewswire.com/news-release/2026/11/09/3398297/0/en/bicara-therapeutics-reports-third-quarter-2026-financial-results-and-provides-business-update.html?ref=bullished.co).

### Sources

- [Bicara Therapeutics Q3 2026 Earnings Call Transcript](https://www.benzinga.com/news/26/11/63033031/bicara-therapeutics-q3-2026-earnings-call-transcript?ref=bullished.co) — benzinga.com
- [Bicara Therapeutics GAAP EPS of -$1.04 misses by $0.22 (BCAX:NASDAQ) | Seeking Alpha](https://seekingalpha.com/news/4668920-bicara-therapeutics-gaap-eps-of-1%5F04-misses-by-0%5F22?ref=bullished.co) — seekingalpha.com
- [Bicara Therapeutics Reports Third Quarter 2026 Financial](https://www.globenewswire.com/news-release/2026/11/09/3398297/0/en/bicara-therapeutics-reports-third-quarter-2026-financial-results-and-provides-business-update.html?ref=bullished.co) — globenewswire.com
- [The company's filing (Bicara Therapeutics)](https://www.sec.gov/Archives/edgar/data/0002023658/000162828026071886/bcax-20261109.htm?ref=bullished.co) — SEC filing
- [Bicara Therapeutics — Form 10-Q for the quarter ended 2026-06-30 (quarterly results)](https://www.sec.gov/Archives/edgar/data/2023658/000162828026055765/bcax-20260630.htm?ref=bullished.co) — SEC EDGAR

### More on Bicara Therapeutics

- [Bicara Plans Survival Analysis As Rival Results Change Its Expectations For Cancer Drug Launch](https://www.bullished.co/bicara-plans-survival-analysis-as-rival-results-change-its-expectations-for-cancer-drug-31219255/)
- [Bicara's Cancer Trials And Launch Preparations Push Quarterly Loss To $71.2 Million](https://www.bullished.co/bicaras-cancer-trials-and-launch-preparations-push-quarterly-loss-to-71-2-million-759bad4d/)

[All Bicara Therapeutics (BCAX) coverage →](https://www.bullished.co/tag/bcax/)